Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Danson

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2006
Melanoma vaccines--they should workS Danson, P Lorigan
Cancer Treatment Reviews|October 5, 2002
Tamoxifen ("Nolvadex"): a reviewM Clemons, S Danson, A Howell
The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland|December 1, 2004
Hormonal and genetic risk factors for breast cancerA Clamp, S Danson, M Clemons
Current Cancer Drug Targets|January 29, 2008
IAPs as a target for anticancer therapyS Danson, E Dean, C Dive, et al.
Cancer Treatment Reviews|April 26, 2001
Locoregionally recurrent breast cancer: incidence, risk factors and survivalM Clemons, S Danson, T Hamilton, et al.
Cancer Treatment Reviews|July 13, 2004
DT-diaphorase: a target for new anticancer drugsS Danson, T H Ward, J Butler, et al.
Cancer Chemotherapy and Pharmacology|March 3, 2007
Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trialS Danson, M Ranson, O Denneny, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancerS Baka, M Ranson, P Lorigan, et al.
British Journal of Cancer|May 20, 2004
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancerS Danson, D Ferry, V Alakhov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaS Danson, P Lorigan, A Arance, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2006
Melanoma vaccines--they should workS Danson, P Lorigan
Cancer Treatment Reviews|October 5, 2002
Tamoxifen ("Nolvadex"): a reviewM Clemons, S Danson, A Howell
The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland|December 1, 2004
Hormonal and genetic risk factors for breast cancerA Clamp, S Danson, M Clemons
Current Cancer Drug Targets|January 29, 2008
IAPs as a target for anticancer therapyS Danson, E Dean, C Dive, et al.
Cancer Treatment Reviews|April 26, 2001
Locoregionally recurrent breast cancer: incidence, risk factors and survivalM Clemons, S Danson, T Hamilton, et al.
Cancer Treatment Reviews|July 13, 2004
DT-diaphorase: a target for new anticancer drugsS Danson, T H Ward, J Butler, et al.
Cancer Chemotherapy and Pharmacology|March 3, 2007
Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trialS Danson, M Ranson, O Denneny, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancerS Baka, M Ranson, P Lorigan, et al.
British Journal of Cancer|May 20, 2004
Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancerS Danson, D Ferry, V Alakhov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaS Danson, P Lorigan, A Arance, et al.
Pageof 2